| AD | Alzheimer’s disease |
| AEP | asparaginyl endopeptidase |
| LGMN | legumain |
| APP | amyloid precursor proteins |
| Aβ | amyloid-β protein |
| Asn | asparagine |
| Asp | asparate |
| TLRs | toll-like receptors |
| APCs | Ag-presenting cells |
| ER | endoplasmic reticulum |
| LSAM | Legumain stabilization and activity modulation |
| MBP | myelin basic protein |
| PD | Parkinson’s disease |
| VD | vascular dementia (VD) |
| FTLD | frontotemporal lobar degeneration (FTLD) |
| DLB | dementia with Lewy bodies |
| APOE4 | apolipoprotein E4 |
| NFTs | neurofibrillary tangles |
| SET | an inhibitor of protein phosphatase 2A |
| PP2A | protein phosphatase 2A |
| C/EBPβ | CCAAT/enhancer binding protein β |
| FSH | follicle-stimulating hormone |
| MCI | mild cognitive impairment |
| CSF | cerebrospinal fluid |
| P-tau | phosphorylated tau |
| PET | positron-emission tomography |
| BBB | blood–brain barrier |
| AuNPs | gold nanoparticles |
| CT | computerized tomography |
| MRI | magnetic resonance imaging |
| TBI | traumatic brain injury |
| tMCAO | transient occlusion of the middle cerebral artery |
| OGD | the oxygen–glucose deprivation |
| Ca2+ | calcium |
| TDP-43 | TAR DNA-binding protein 43 |
| GBM | glioblastoma |